Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction

The Journal of Urology

Volumn 153, Issue 6, 1995, Pages 1828-1830

  Kim, Edward D ^a   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTAGLANDIN E1;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMPOTENCE; MALE; PENIS ERECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SPINAL CORD INJURY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; ALPROSTADIL; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 0029043759     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)67323-3     Document Type: Article

References (18)

1. Pharmacological erection program using prostaglandin E1
2. Intracavernous injection therapy: analysis of results and complications
3. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence
4. Treatment of erectile dysfunction in men with diabetes mellitus using a penetration-enhanced topical minoxidil solution
5. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury
6. Topical minoxidil in the treatment of male erectile dysfunction
7. Nitroglycerin ointment in the treatment of impotence
8. Topical nitroglycerin: a potential treatment for impotence
9. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction
10. Papaverine topical gel for treatment of erectile dysfunction
11. Sexual dysfunction after spinal cord injury
12. The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: a three-year follow up
13. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease
14. Regional variation in percutaneous penetration in man
15. Inhibitory effect of prostaglandin E sub 1 on laurate-induced peripheral vascular occlusive sequelae in rabbits: optimized topical formulation with beta-cyclodextrin derivative and penetration enhancer HPE-101
16. The relationship between time of application of prostaglandin E1 and improved flap survival
17. Improved transdermal delivery of prostaglandin E sub 1 through hairless mouse skin: combined use of carboxymethylethyl-beta-cyclodextrin and penetration enhancers
18. Aspects of the transdermal delivery of prostaglandins